PharmaResearch, Medical device 'Rejuran®HB plus' acquired product approval

Reduced pain, Upgrade version of Rejuran® … Sales start in the second half of the year

PharmaResearch (CEO Kim Shin-Kyu, Kang Ki-Seock) announced on the 30th that the PN (polynucleotide) component medical device, 'Rejuran®HB Plus' has approved by the Ministry of Food and Drug Safety and will start full-scale sales from the second half of the year.

Rejuran®HB Plus is an upgraded version that contains additional hyaluronic acid (HA) and lidocaine to the existing PN ingredient. It reduces pain as it includes lidocaine, and the synergy with the added HA improves efficiency.

Rejuran®HB Plus is used to improve Crow's Feet through physical restoration by injecting PN and HA subcutaneously.

PharmaResearch has further reinforced its aesthetic portfolio by adding Rejuran® HB Plus to Rejuran®, Rejumate® Injector (automatic drug injector), Re N Tox® (Botulinum Toxin), and Rejuviel® (dermal filler).

An official from PharmaResearch said, "Rejuran® HB Plus is a product that can produce satisfactory effects with less pain compared to existing Rejuran products." The official also added that "the sale will hit the ground running in the second half of this year."

Meanwhile, PharmaResearch is a regenerative medicine-based biopharmaceutical company that manufactures and sells pharmaceuticals, medical devices, cosmetics, and health functional foods, focusing on tissue regeneration materials, DOT™ PDRN and DOT™ PN. The top line of the products are Rejuran®, Conjuran®, Rejuran®Cosmetic, Re-An® Eye drops.